Special Feature Brief Communication | Published:

1-Amino-2′-fucosyllactose inhibits biofilm formation by Streptococcus agalactiae

The Journal of Antibiotics (2019) | Download Citation



2′-Fucosyllactose (2′-FL) is a ubiquitous oligosaccharide in human milk. Importantly, this carbohydrate promotes the growth of several strains of Bifidobacteria, a class of beneficial gut commensal, and inhibits epithelial binding of pathogens. In light of these protective effects, we elected to evaluate the potential of 2′-FL to serve as an antibacterial agent against Group B Streptococcus (GBS). While 2′-FL was devoid of any substantial antimicrobial or antibiofilm activity, conversion of 2′-FL to its reducing end β-amine provided a novel antibiofilm compound.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003;2:114–22. https://doi.org/10.1038/nrd1008

  2. 2.

    Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–22.

  3. 3.

    Flemming H-C, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010;8:623–33. https://doi.org/10.1038/nrmicro2415

  4. 4.

    Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. https://doi.org/10.1111/apm.12099 (2013).

  5. 5.

    Wu H, Moser C, Wang HZ, Hoiby N, Song ZJ. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015;7:1–7. https://doi.org/10.1038/ijos.2014.65

  6. 6.

    Sabir N, et al. Bacterial biofilm-based catheter-associated urinary tract infections: causative pathogens and antibiotic resistance. Am J Infect Control. 2017;45:1101–5. https://doi.org/10.1016/j.ajic.2017.05.009

  7. 7.

    Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358:135–8.

  8. 8.

    Hoiby N, et al. The clinical impact of bacterial biofilms. Int J Oral Sci. 2011;3:55–65. https://doi.org/10.4248/IJOS11026

  9. 9.

    Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95–108. https://doi.org/10.1038/nrmicro821

  10. 10.

    de Beer D, Stoodley P, Roe F, Lewandowski Z. Effects of biofilm structures on oxygen distribution and mass transport. Biotechnol Bioeng. 1994;43:1131–8. https://doi.org/10.1002/bit.260431118

  11. 11.

    Ackerman DL, et al. Antimicrobial and antibiofilm activity of human milk oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii. ACS Infect Dis. 2018;4:315–24. https://doi.org/10.1021/acsinfecdis.7b00183

  12. 12.

    Ackerman DL, et al. Human Milk oligosaccharides exhibit antimicrobial and antibiofilm properties against group B streptococcus. ACS Infect Dis. 2017;3:595–605. https://doi.org/10.1021/acsinfecdis.7b00064

  13. 13.

    Craft KM, Thomas HC & Townsend SD. Interrogation of human milk oligosaccharide fucosylation patterns for antimicrobial and antibiofilm trends in Group B streptococcus. ACS Infect Dis. https://doi.org/10.1021/acsinfecdis.8b00234 (2018).

  14. 14.

    Craft KM, Thomas HC & Townsend SD. Sialylated variants of lacto-N-tetraose exhibit antimicrobial activity against Group B Streptococcus. Org Biomol Chem. https://doi.org/10.1039/c8ob02080a (2018).

  15. 15.

    Craft KM, Gaddy JA, Townsend SD. Human milk oligosaccharides (HMOs) sensitize Group B streptococcus to clindamycin, erythromycin, gentamicin, and minocycline on a strain specific basis. ACS Chem Biol. 2018;13:2020–6. https://doi.org/10.1021/acschembio.8b00661

  16. 16.

    Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012;22:1147–62. https://doi.org/10.1093/glycob/cws074

  17. 17.

    Castanys-Munoz E, Martin MJ, Prieto PA. 2’-fucosyllactose: an abundant, genetically determined soluble glycan present in human milk. Nutr Rev. 2013;71:773–89. https://doi.org/10.1111/nure.12079

  18. 18.

    Craft KM & Townsend SD. The human milk glycome as a defense against infectious diseases: rationale, challenges, and opportunities. ACS Infect Dis. https://doi.org/10.1021/acsinfecdis.7b00209 (2017).

  19. 19.

    Melin P, Efstratiou A. Group B streptococcal epidemiology and vaccine needs in developed countries. Vaccine. 2013;31(Suppl 4):D31–42. https://doi.org/10.1016/j.vaccine.2013.05.012

  20. 20.

    Cieslewicz MJ, et al. Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infect Immun. 2005;73:3096–103. https://doi.org/10.1128/IAI.73.5.3096-3103.2005

  21. 21.

    Morrow AL, et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr. 2004;145:297–303. https://doi.org/10.1016/j.jpeds.2004.04.054

  22. 22.

    Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg DS. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem. 2003;278:14112–20. https://doi.org/10.1074/jbc.M207744200

  23. 23.

    Markowitz J, et al. Structural characterization of NRAS isoform 5. Protein Sci. 2016;25:1069–74. https://doi.org/10.1002/pro.2916

  24. 24.

    Koromyslova A, Tripathi S, Morozov V, Schroten H, Hansman GS. Human norovirus inhibition by a human milk oligosaccharide. Virology. 2017;508:81–89. https://doi.org/10.1016/j.virol.2017.04.032

  25. 25.

    Marotta M, Ryan JT, Hickey RM. The predominant milk oligosaccharide 6′-sialyllactose reduces the internalisation of Pseudomonas aeruginosa in human pneumocytes. J Funct Foods. 2014;6:367–73. https://doi.org/10.1016/j.jff.2013.10.026

  26. 26.

    Weichert S, et al. Bioengineered 2′-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines. Nutr Res. 2013;33:831–8. https://doi.org/10.1016/j.nutres.2013.07.009

  27. 27.

    del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther. 2007;82:204–9. https://doi.org/10.1038/sj.clpt.6100247

  28. 28.

    Donelli G, Francolini I, Piozzi A, Di Rosa R, Marconi W. New polymer-antibiotic systems to inhibit bacterial biofilm formation: a suitable approach to prevent central venous catheter-associated infections. J Chemother. 2002;14:501–7. https://doi.org/10.1179/joc.2002.14.5.501

  29. 29.

    Meeker DG, et al. Versatility of targeted antibiotic-loaded gold nanoconstructs for the treatment of biofilm-associated bacterial infections. Int J Hyperth. 2018;34:209–19. https://doi.org/10.1080/02656736.2017.1392047

  30. 30.

    Saini H, Vadekeetil A, Chhibber S & Harjai K. Azithromycin-ciprofloxacin-impregnated urinary catheters avert bacterial colonization, biofilm formation, and inflammation in a murine model of foreign-body-associated urinary tract infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01906-16 (2017).

  31. 31.

    Jain T, et al. Biofilm inhibition and anti-Candida activity of a cationic lipo-benzamide molecule with twin-nonyl chain. Bioorg Med Chem Lett. 2018;28:1776–80. https://doi.org/10.1016/j.bmcl.2018.04.024

  32. 32.

    Perez-Soto N, et al. Engineering microbial physiology with synthetic polymers: cationic polymers induce biofilm formation in Vibrio cholerae and downregulate the expression of virulence genes. Chem Sci. 2017;8:5291–8. https://doi.org/10.1039/c7sc00615b

  33. 33.

    Algburi A et al. Gemini cationic amphiphiles control biofilm formation by bacterial vaginosis pathogens. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.00650-17 (2017).

  34. 34.

    Takahashi H, Nadres ET, Kuroda K. Cationic amphiphilic polymers with antimicrobial activity for oral care applications: eradication of s. mutans biofilm. Biomacromolecules. 2017;18:257–65. https://doi.org/10.1021/acs.biomac.6b01598

  35. 35.

    Kreling PF, et al. Cytotoxicity and the effect of cationic peptide fragments against cariogenic bacteria under planktonic and biofilm conditions. Biofouling. 2016;32:995–1006. https://doi.org/10.1080/08927014.2016.1218850

  36. 36.

    de la Fuente-Nunez C, et al. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother. 2012;56:2696–704. https://doi.org/10.1128/AAC.00064-12

  37. 37.

    Likhosherstov LM, Novikova OS, Derevitskaja VA, Kochetkov NK. A new simple synthesis of amino sugar beta-D-glycosylamines. Carbohydr Res. 1986;146:C1–C5. https://doi.org/10.1016/0008-6215(86)85037-6

Download references


This material is based upon work supported by the National Science Foundation under Grant No. [1847804]. This work was also supported by Vanderbilt University, the Vanderbilt Microbiome Initiative (VMI), the Department of Pediatrics at Vanderbilt University Medical Center, and Prolacta Bioscience for S.D.T. K.M.C. was supported by the Vanderbilt Chemical Biology Interface (CBI) training program (T32 GM065086), the Vanderbilt Pre3 Initiative (travel grant), and the Mitchum E. Warren, Jr. Graduate Research Fellowship. Prof. Jennifer Gaddy is acknowledged for use of her facilities. Prof. Shannon Manning at Michigan State University is acknowledged for generously providing clinical strains of GBS (GBS590 and GBS2). Harrison Thomas is acknowledged for his assistance with the viability and biofilm assays. Ryan Doster is acknowledged for discussions regarding experimental design. Jacky Lu is acknowledged for his assistance with bacterial culturing.

Author information


  1. Department of Chemistry, Vanderbilt University, 7330 Stevenson Center, Nashville, TN, 37235, USA

    • Kelly M. Craft
    •  & Steven D. Townsend
  2. Institute of Chemical Biology, Vanderbilt University, 896 Preston Research Building, Nashville, TN, 37232, USA

    • Steven D. Townsend
  3. Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University, Medical Center North A-5302, 1161 21st Ave South, Nashville, TN, 37232, USA

    • Steven D. Townsend


  1. Search for Kelly M. Craft in:

  2. Search for Steven D. Townsend in:

Conflict of interest

The authors declare that they have no conflict to declare.

Corresponding author

Correspondence to Steven D. Townsend.

Supplementary information

About this article

Publication history